BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression
Biond is an innovative biotech company developing unique and breakthrough therapies for the treatment of cancer.
Biond is an innovative biotech company developing unique and breakthrough therapies for the treatment of cancer.
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression